Hemoglobinopathies Market

Market Definition

Global Hemoglobinopathies market size is valued at USD 7.2 billion in 2025 and projected to grow at a CAGR of 18.2% during the forecast period, reaching USD 27.4 billion by 2033

Hemoglobinopathies are a group of disorders inherited in which there is abnormal production or structure of the hemoglobin molecule. Sickle cell disease (SCD) and thalassemia are blood disorders caused by abnormal hemoglobin that damages and deforms red blood cells.

Market Dynamics

The rising prevalence of hemoglobinopathies is boosting the market growth. For instance, approximately 7% of the worldwide population have hemoglobinopathies and are the most common monogenic diseases. Sickle Cell Disease (SCD) is the most common inherited blood disorder in the United States. According to the Centers for Disease Control and Prevention (CDC), Sickle Cell Disease (SCD) affects approximately 100,000 Americans in 2020. Sickle Cell Disease occurs among 1 out of every 16,300 Hispanic-American births. The prevalence of beta-thalassemia globally is around 288,000, with an incidence of 60,000 births per year. Beta-thalassemia is prevalent in developing countries of Africa, South Asia, Southeast Asia, the Mediterranean region and the Middle East. The total prevalence of beta-thalassemia in the European Union and the United States is estimated to be approximately 19,000 patients. Every year approximately 100,000 children are born with Thalassemia Major around the world, of which 10,000 are born in India. Further, favorable government programs related to hemoglobinopathy are a key driving factor of the market. However, product recall might hamper the market growth. Moreover, an increasing clinical trial for hemoglobinopathies therapy would provide lucrative opportunities for the market in coming years.

Market Segmentation

The global hemoglobinopathies market is mainly classified based on type, end-user, and test type. Type is further segmented into Thalassemia, Sickle Cell Disease, and Others. By end-user, the market is divided into Hospitals, Diagnostics Laboratories, and Others. By test type, the market is further divided into Genetic Testing, Routine Red Blood Cell (RBC) Count, Hemoglobin Isoelectric Focusing (Hb IEF), Hemoglobin electrophoresis (Hb ELP), and Others.

Based on Type, Thalassemia segment is valued at USD 4 billion in 2026 and is projected to reach USD 11.9 billion by 2033, at a CAGR of 16.8% during the forecast period.

Based on end-user, Hospitals segment is projected to reach USD 13.8 billion by 2033, at a CAGR of 17% during the forecast period.

Based on test type, Genetic Testing segment is projected to reach USD 12.3 billion by 2033. 

Regional Analysis

Based on geography, the global hemoglobinopathies market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided into the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America is expected to dominate the hemoglobinopathies market in 2021 due to the rising incident and prevalence of hemoglobinopathies, commercialization of regulatory approval of hemoglobinopathies therapy, and increasing clinical studies on hemoglobinopathies therapy. For instance, Imara Inc., a clinical-stage biopharmaceutical company that develops and commercializes therapeutics to treat patients suffering from inherited genetic disorders of hemoglobin, has introduced the company’s Forte Phase 2b clinical trials of IMR-687 for patients with beta-thalassemia. IMR-687 is designed to have a multimodal mechanism action on red blood cells, white blood cells, adhesion mediators and other cell types.

Competitive landscape

Key players operating in the hemoglobinopathies industry include Bio-Rad Laboratories, Inc., Shenzhen Mindray Bio-Medical Electronics Co., Ltd, PerkinElmer Inc., Sysmex Corporation, Novartis AG, Emmaus Medical, Bristol-Myers Squibb Company, ApoPharma Inc, Gamida Cell, and Acceleron Pharma, Inc.

Raising funds for the development of hemoglobinopathies products, commercialization of regulatory approved hemoglobinopathies therapy, increasing clinical trials for the hemoglobinopathies therapy, and the collaboration between companies and private foundation for the development of hemoglobinopathies therapy products are some of the strategies adopted by the major companies. For instance, on February 17, 2021, Novartis has entered into a grant agreement with the Bill & Melinda Gates Foundation. Based on the agreement, the foundation will provide funding support for the development of a single-administration, in vivo gene therapy for the treatment of sickle cell disease (SCD). The objectives of the project is to expand access to healthcare in low-resource settings in an effort to address sickle cell disease (SCD) life-threatening genetic disease.

Hemoglobinopathies Market Key Segments:

By Type

• Thalassemia
• Sickle Cell Disease
• Others

By End-User

• Hospitals
• Diagnostics Laboratories
• Others

By Test Type

• Genetic Testing
• Routine Red Blood Cell (RBC) Count
• Hemoglobin Isoelectric Focusing (Hb IEF)
• Hemoglobin electrophoresis (Hb ELP)
• Others

Key Global Hemoglobinopathies Industry Players

• Bio-Rad Laboratories, Inc.
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd
• PerkinElmer Inc.
• Sysmex Corporation
• Novartis AG
• Emmaus Medical
• Bristol-Myers Squibb Company
• ApoPharma Inc
• Gamida Cell
• Acceleron Pharma, Inc

Report Attributes	Details
Study Period	2021-2033
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2033
Historical Period	2021-2025
Growth Rate	CAGR 18.2% from 2026 to 2033
Revenue Unit	USD billion
Sales Volume Unit	Thousand Units
Segmentation	By Type, End-User, Test Type and Region
By Region	North America (By Type, End-User, Test Type and Country) United States Canada Mexico
	Europe (By Type, End-User, Test Type and Country) Germany France UK Italy Spain Russia Rest of the Europe
	Asia Pacific (By Type, End-User, Test Type and Country) China Japan India South Korea Australia Southeast Asia Rest of Asia Pacific
	South America (By Type, End-User, Test Type and Country) Brazil Argentina Rest of South America
	Middle East and Africa (By Type, End-User, Test Type and Country) Saudi Arabia UAE South Africa Rest of Middle East and Africa

What Report Provides

• Key Company Market Share, Revenue, and Position/Ranking
• Key Market Leaders
• Full In-Depth Analysis of the Parent Industry
• Industry Statistics
• Important Changes in Market and Its Dynamics
• Segmentation Details of the Market
• Historical, On-Going, and Projected Market Analysis
• Assessment of Niche Industry Developments
• Market Share Analysis
• Key Strategies of Major Players
• Company Profiles of Key Players
• Unique Selling Prepositions of Leading Market Players
• Emerging Segments and Regional Growth Potential
• Key Strategic Recommendations
• Competitive Benchmarking
• Import Export Trade Statistics